The bioactive alkaloids identified from Cortex Phellodendri ameliorate benign prostatic hyperplasia via LOX-5/COX-2 pathways

Phytomedicine. 2021 Dec:93:153813. doi: 10.1016/j.phymed.2021.153813. Epub 2021 Oct 19.

Abstract

Background: The bioactive alkaloids identified from Cortex Phellodendri (CP) were highly effective in treating rats with benign prostatic hyperplasia (BPH). Specifically, lipoxygenase-5 (LOX-5) and cyclooxygenase-2 (COX-2) were identified as two primary targets for alleviating inflammation in BPH rats. However, it remains unknown whether the alkaloid components in CP can interact with the two target proteins.

Purpose: To further identify bioactive alkaloids targeting LOX/COX pathways.

Methods: An affinity-ultrafiltration mass spectrometry approach was employed to screen dual-target LOX-5/COX-2 ligands from alkaloid extract. The structures of bioactive alkaloids were characterized by high-resolution Fourier transform ion cyclotron resonance mass spectrometry. To understand the molecular mechanisms underlying the effects of bioactive alkaloids, the expression levels of LOX-5 and COX-2 in BPH model rats were investigated at both protein and mRNA levels. The LOX-5/COX-2 enzymes activity experiments and molecular docking analysis were performed to fully evaluate the interactions between bioactive alkaloids and LOX-5/COX-2.

Results: After comprehensive analysis, the results showed that bioactive alkaloids could suppress the expression of LOX-5 and COX-2 simultaneously to exert an anti-inflammatory effect on the progression of BPH. In addition, the screened protoberberine, demethyleneberberine was found to exhibit prominent inhibitory activities against both LOX-5 and COX-2 enzymes, palmatine and berberine with moderate inhibitory activities. Molecular docking analysis confirmed that demethyleneberberine could interact well with LOX-5/COX-2.

Conclusion: This study is the first to explore the inhibitory effects of bioactive alkaloids from CP on LOX-5 and COX-2 activities in BPH rats. Our findings demonstrate that the bioactive alkaloids from CP can ameliorate BPH via dual LOX-5/COX-2 pathways, which serves as an efficient approach for the discovery of novel drug leads from natural products with reduced side effects.

Keywords: Affinity ultrafiltration; Benign prostatic hyperplasia; Bioactive alkaloids; Lipoxygenase-5/cyclooxygenase-2 pathways; Target expression.

MeSH terms

  • Alkaloids* / pharmacology
  • Animals
  • Arachidonate 5-Lipoxygenase
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Humans
  • Lipoxygenase
  • Lipoxygenase Inhibitors
  • Male
  • Molecular Docking Simulation
  • Prostatic Hyperplasia* / drug therapy
  • Rats

Substances

  • Alkaloids
  • Cyclooxygenase 2 Inhibitors
  • Lipoxygenase Inhibitors
  • Lipoxygenase
  • Arachidonate 5-Lipoxygenase
  • Cyclooxygenase 2